Biopharma Stock Updates - 12/09/20

Data Updates:

$GMDA (-13.3%) – Topline phase 3 results & BLA plans

$CYTK (+22.8%) – Phase 2 interim analysis – proceed to cohort 2

$ATNX (-3.3%) – Updated phase 3 data for oraxol

$EDIT (+17%) – Submitted IND for EDIT-301 in SCD

$FPRX (-12.5%) – Will present phase 2 data at ASCO 01/15/21

$GTHX (-7.5%) – Phase 2 data for Triliciclib and phase 1 update


$KURA (-1.2%) – Priced their offering at $37/share

$SNDX (+7%) – Priced their offering at $23/share

$MIRM (+0.67%) - $210 million funding arrangement – tiered revenue-based


*Disclaimer: Information provided on and in any of our reports, products and services are for information only and are not investment advice. Please consult with an investment adviser and do your own diligence before making any investment decisions or taking any action.  By accessing this site, you agree to our Terms of Use and Privacy Policy that can be accessed here. Big Movers™ is a trademark of Amp Biotech Research, LLC

©2021 by Biopharm IQ. Website by Awaken Studio.